Gilead Sciences Now Covered by Argus (GILD)

Share on StockTwits

Argus assumed coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report issued on Monday. The firm issued a buy rating and a $110.00 target price on the stock.

In other Gilead Sciences news, Director Richard James Whitley unloaded 5,000 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $91.00, for a total transaction of $455,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences (NASDAQ:GILD) traded up 0.18% on Monday, hitting $93.089. The stock had a trading volume of 5,512,570 shares. Gilead Sciences has a 52 week low of $55.96 and a 52 week high of $94.34. The stock has a 50-day moving average of $88.49 and a 200-day moving average of $80.80. The company has a market cap of $140.7 billion and a price-to-earnings ratio of 21.05. Gilead Sciences also saw a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 98,473,543 shares, an increase of 3.1% from the July 15th total of 95,485,621 shares. Based on an average daily trading volume, of 14,643,274 shares, the days-to-cover ratio is presently 6.7 days. Approximately 6.5% of the company’s stock are short sold.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company posted $0.50 earnings per share. Gilead Sciences’s revenue was up 136.1% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $8.02 earnings per share for the current fiscal year.

GILD has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Gilead Sciences from a neutral rating to an outperform rating in a research note on Thursday, August 7th. They now have a $111.00 price target on the stock. Finally, analysts at Maxim Group raised their price target on shares of Gilead Sciences from $112.00 to $127.00 in a research note on Monday, July 28th. They now have a buy rating on the stock. One analyst has rated the stock with a hold rating and nineteen have given a buy rating to the stock. Gilead Sciences presently has an average rating of Buy and an average price target of $103.32.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Receive News & Ratings for Gilead Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Samsung Promises Changes as Profit Plunges
Samsung Promises Changes as Profit Plunges
Advertising Revenue at Facebook Surges
Advertising Revenue at Facebook Surges
Lloyds Bank Cutting 9,000 Jobs and Closing Branches
Lloyds Bank Cutting 9,000 Jobs and Closing Branches
Goldman Sachs Cuts Forecast for Oil Price in 2015
Goldman Sachs Cuts Forecast for Oil Price in 2015
Eli Lilly Earnings Meet Expectations
Eli Lilly Earnings Meet Expectations
Microsoft Sales Pass Street Estimates
Microsoft Sales Pass Street Estimates


Leave a Reply

Advertisement
Advertisement
© 2006-2014 Ticker Report. Google+.